Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04157127 · ClinicalTrials.gov registry record · Phase 1
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
A Phase 1 study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Diakonos Oncology Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT04157127 is a Phase 1 study of Pancreatic Cancer and Pancreatic Adenocarcinoma that is actively recruiting participants, run by Diakonos Oncology Corporation. The registered enrollment target is 18 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT04157127, a Phase 1 study of Pancreatic Cancer and Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Diakonos Oncology Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.
Conditions Studied
Interventions
- BIOLOGICAL Autologous DC Therapy
Study Locations (3)
Texas
- Baylor College of Medicine Medical Center - McNair Campus - Houston
- Baylor St. Lukes Medical Center - Houston
- Dan L. Duncan Cancer Center at Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04157127
The ClinicalTrials.gov registry entry for NCT04157127 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Diakonos Oncology Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Autologous DC Therapy is the first listed.
NCT04157127 reports 3 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04157127 about?
NCT04157127 is a clinical study titled "Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma". This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.
What is the current status of trial NCT04157127?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-08-03. Estimated completion is 2027-12.
What conditions does trial NCT04157127 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma.
What interventions are being tested in trial NCT04157127?
The interventions under investigation include: Autologous DC Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04157127?
This trial is sponsored by Diakonos Oncology Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04157127 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.